Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.
Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Oral Cavity (Mouth) Cancer.